Enzolytics, Inc. (OTCMKTS:ENZC) Sees Large Decline in Short Interest

Enzolytics, Inc. (OTCMKTS:ENZC) saw a large decrease in short interest in October. As of October 31st, there was short interest totalling 291,200 shares, a decrease of 76.9% from the October 15th total of 1,260,500 shares. Based on an average daily volume of 15,310,300 shares, the short-interest ratio is presently 0.0 days.

Enzolytics Price Performance

ENZC stock remained flat at $0.00 during trading hours on Tuesday. 40,385,520 shares of the company’s stock were exchanged, compared to its average volume of 10,738,604. Enzolytics has a 12-month low of $0.00 and a 12-month high of $0.03.

Enzolytics Company Profile

Enzolytics Inc, a drug development company, focuses to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases. Its patented anti-HIV therapeutics and a proprietary methodology for producing human IgG1 monoclonal antibodies for treating infectious diseases with non-toxic passive immunotherapy.